# BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary

> **NCT06304922** · — · UNKNOWN · sponsor: **Assiut University** · enrollment: 45 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **BEHAVIORAL:** Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer

## Key facts

- **NCT ID:** NCT06304922
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-01
- **Primary completion:** 2025-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06304922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06304922, "BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06304922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*